Interpretation of the key points of Cancer Incidence and Mortality in China, 2016_Chinese Journal of Clinical Thoracic and Cardiovascular Surgery

Authors：

XU Ruifeng ¹ , SUN Xin ¹ , TIAN Yu ² , REN Na ¹ , XING Qi ¹ , MENG Fanmao ¹ ,  ZHANG Guochao ¹ ,  ZHAO Liang ¹

1. National Cancer Center, National Cancer Clinical Medical Research Center, Cancer Hospital Chinese Academy of Medical Sciences, Beijing, 100021, P. R. China;
2. School of Public Health, Capital Medical University, Beijing, 100069, P. R. China;

Corresponding author：

ZHANG Guochao, Email: 18801038718@163.com; ZHAO Liang, Email: drzhaoliang@126.com

Keywords：

Cancer data; cancer incidence; cancer mortality; cancer prevention and treatment; interpretation of cancer data in 2016

DOI：

10.7507/1007-4848.202312022

Video：

Export PDF Favorites Scan Get Citation

Abstract Full text Figures/Tables Video References Cited by

In 2022, the National Cancer Center (NCC) of China reported the nationwide statistics of 2016 using population-based cancer registry data from all available cancer registries in China, which was mainly about the cancer incidence and mortality. Cancer remains a major health problem currently in our country and requires long term cooperation to deal with. This article provided a key point interpretation and analysis of cancer prevalence data in China, and provided an analysis of several main risk factors for cancer, which was conducive to the development of cancer prevention and control programs in different regions.

Citation： XU Ruifeng, SUN Xin, TIAN Yu, REN Na, XING Qi, MENG Fanmao, ZHANG Guochao, ZHAO Liang. Interpretation of the key points of Cancer Incidence and Mortality in China, 2016. Chinese Journal of Clinical Thoracic and Cardiovascular Surgery, 2024, 31(3): 343-356. doi: 10.7507/1007-4848.202312022 Copy

1.	Zheng RS, Zhang SW, Sun KX, et al. Cancer statistics in China, 2016. Zhonghua Zhong Liu Za Zhi, 2023, 45(3): 212-220.
2.	Wei W, Zeng H, Zheng R, et al. Cancer registration in China and its role in cancer prevention and control. Lancet Oncol, 2020, 21(7): e342-e349.
3.	Fan L, Strasser-Weippl K, Li JJ, et al. Breast cancer in China. Lancet Oncol, 2014, 15(7): e279-e289.
4.	Xi L, Zhu J, Zhang H, et al. Epidemiological trends in gastrointestinal cancers in China: An ecological study. Dig Dis Sci, 2019, 64(2): 532-543.
5.	Deo SVS, Sharma J, Kumar S. GLOBOCAN 2020 report on global cancer burden: Challenges and opportunities for surgical oncologists. Ann Surg Oncol, 2022, 29(11): 6497-6500.
6.	Lu Y, Song S, Wang R, et al. Impacts of soil and water pollution on food safety and health risks in China. Environ Int, 2015, 77: 5-15.
7.	Liu J, Zhang S, Wang Q, et al. Seroepidemiology of hepatitis B virus infection in 2 million men aged 21-49 years in rural China: A population-based, cross-sectional study. Lancet Infect Dis, 2016, 16(1): 80-86.
8.	Jiafang Z, Jiachun W, Yunxia L, et al. Alcohol abuse in a metropolitan city in China: A study of the prevalence and risk factors. Addiction, 2004, 99(9): 1103-1110.
9.	Ma Z, Lv J, Zhu M, et al. Lung cancer risk score for ever and never smokers in China. Cancer Commun (Lond), 2023, 43(8): 877-895.
10.	Mema SC, Baytalan G. Radon and lung cancer risk. CMAJ, 2023, 195(24): E850.
11.	Arnold M, Abnet CC, Neale RE, et al. Global burden of 5 major types of gastrointestinal cancer. Gastroenterology, 2020, 159(1): 335-349.
12.	Feng X, Wang F, Yang W, et al. Association between genetic risk, adherence to healthy lifestyle behavior, and thyroid cancer risk. JAMA Netw Open, 2022, 5(12): e2246311.
13.	Johnstone SE, Gladyshev VN, Aryee MJ, et al. Epigenetic clocks, aging, and cancer. Science, 2022, 378(6626): 1276-1277.
14.	Yang J, Siri JG, Remais JV, et al. The Tsinghua-Lancet commission on healthy cities in China: Unlocking the power of cities for a healthy China. Lancet, 2018, 391(10135): 2140-2184.
15.	Lester SP, Kaur AS, Vegunta S. Association between lifestyle changes, mammographic breast density, and breast cancer. Oncologist, 2022, 27(7): 548-554.
16.	Ullmann TM, Papaleontiou M, Sosa JA. Current controversies in low-risk differentiated thyroid cancer: Reducing overtreatment in an era of overdiagnosis. J Clin Endocrinol Metab, 2023, 108(2): 271-280.
17.	Miller KD, Fidler-Benaoudia M, Keegan TH, et al. Cancer statistics for adolescents and young adults, 2020. CA Cancer J Clin, 2020, 70(6): 443-459.
18.	黄渺新, 钟福兴, 郭少华, 等. 对恶性肿瘤年轻化趋势的分析研究. 中国医师进修杂志, 2006, 29(9): 53-54.
19.	Li X, Zheng R, Li X, et al. Trends of incidence rate and age at diagnosis for cervical cancer in China, from 2000 to 2014. Chin J Cancer Res, 2017, 29(6): 477-486.
20.	Sung H, Ferlay J, Siegel RL, et al. Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA, 2021, 71(3): 209-249.
21.	Kjaer TK, Andersen EAW, Ursin G, et al. Cumulative incidence of second primary cancers in a large nationwide cohort of Danish cancer survivors: A population-based retrospective cohort study. Lancet Oncol, 2023, S1470-2045, Epub ahead of print.
22.	赵洁敏, 吴昌平. 多原发癌症的研究进展. 癌症进展, 2016, 14(12): 1195-1198.
23.	Ye Y, Neil AL, Wills KE, et al. Temporal trends in the risk of developing multiple primary cancers: A systematic review. BMC Cancer, 2016, 16(1): 849.
24.	Curtis RE, Freedman DM, Ron E, et al. New malignancies among cancer survivors: SEER Cancer Registries, 1973-2000. J Epidemiol Comm Health, 2008, 62(4): 375-376.
25.	Buzzoni C, Crocetti E, Bella F, et al. Italian cancer figures, report 2013: Multiple tumours. Epidemiol Prev, 2013, 37(4-5): 1-156.
26.	Jégu J, Colonna M, Daubisse-Marliac L, et al. The effect of patient characteristics on second primary cancer risk in France. BMC Cancer, 2014, 14: 94.
27.	Youlden DR, Baade PD. The relative risk of second primary cancers in Queensland, Australia: A retrospective cohort study. BMC Cancer, 2011, 11: 83.
28.	Sankila R, Pukkala E, Teppo L. Risk of subsequent malignant neoplasms among 470, 000 cancer patients in Finland, 1953-1991. Int J Cancer, 1995, 60(4): 464-470.
29.	Tsukuma H, Fujimoto I, Hanai A, et al. Incidence of second primary cancers in Osaka residents, Japan, with special reference to cumulative and relative risks. Jpn J Cancer Res, 1994, 85(4): 339-345.
30.	Rebora P, Czene K, Antolini L, et al. Are chronic myeloid leukemia patients more at risk for second malignancies? A population-based study. Am J Epidemiol, 2010, 172(9): 1028-1033.
31.	Schöllkopf C, Rosendahl D, Rostgaard K, et al. Risk of second cancer after chronic lymphocytic leukemia. Int J Cancer, 2007, 121(1): 151-156.
32.	Hisada M, Chen BE, Jaffe ES, et al. Second cancer incidence and cause-specific mortality among 3104 patients with hairy cell leukemia: A population-based study. J Natl Cancer Inst, 2007, 99(3): 215-222.
33.	Federico M, Zinzani PL, Frassoldati A, et al. Risk of second cancer in patients with hairy cell leukemia: Long-term follow-up. J Clin Oncol, 2002, 20(3): 638-646.
34.	Coleman MP, Bell CM, Fraser P. Second primary malignancy after Hodgkin’s disease, ovarian cancer and cancer of the testis: A population-based cohort study. Br J Cancer, 1987, 56(3): 349-355.
35.	Rossi C, Jégu J, Mounier M, et al. Risk assessment of second primary cancer according to histological subtype of non-Hodgkin lymphoma. Leuk Lymphoma, 2015, 56(10): 2876-2882.
36.	Razavi P, Rand KA, Cozen W, et al. Patterns of second primary malignancy risk in multiple myeloma patients before and after the introduction of novel therapeutics. Blood Cancer J, 2013, 3(6): e121.
37.	Mellemkjaer L, Friis S, Olsen JH, et al. Risk of second cancer among women with breast cancer. Int J Cancer, 2006, 118(9): 2285-2292.
38.	Brown LM, Chen BE, Pfeiffer RM, et al. Risk of second non-hematological malignancies among 376, 825 breast cancer survivors. Breast Cancer Res Treat, 2007, 106(3): 439-451.
39.	Molina-Montes E, Pollán M, Payer T, et al. Risk of second primary cancer among women with breast cancer: A population-based study in Granada (Spain). Gynecol Oncol, 2013, 130(2): 340-345.
40.	Cho YY, Lim J, Oh CM, et al. Elevated risks of subsequent primary malignancies in patients with thyroid cancer: A nationwide, population-based study in Korea. Cancer, 2015, 121(2): 259-268.
41.	Kim C, Bi X, Pan D, et al. The risk of second cancers after diagnosis of primary thyroid cancer is elevated in thyroid microcarcinomas. Thyroid, 2013, 23(5): 575-582.
42.	Joung JY, Lim J, Oh CM, et al. Risk of second primary cancer among prostate cancer patients in Korea: A population-based cohort study. PLoS One, 2015, 10(10): e0140693.
43.	Levi F, Randimbison L, Te VC, et al. Second primary tumors after prostate carcinoma. Cancer, 1999, 86(8): 1567-1570.
44.	Bao X, Cao L, Piao H, et al. Treatment-related secondary cancer in malignant meningiomas: A population-based study. J Cancer Res Clin Oncol, 2014, 140(4): 583-588.
45.	Jégu J, Binder-Foucard F, Borel C, et al. Trends over three decades of the risk of second primary cancer among patients with head and neck cancer. Oral Oncol, 2013, 49(1): 9-14.
46.	Zhu G, Chen Y, Zhu Z, et al. Risk of second primary cancer after treatment for esophageal cancer: A pooled analysis of nine cancer registries. Dis Esophagus, 2012, 25(6): 505-511.
47.	Scélo G, Boffetta P, Autier P, et al. Associations between ocular melanoma and other primary cancers: An international population-based study. Inter J Cancer, 2007, 120(1): 152-159.
48.	Howard RA, Dores GM, Curtis RE, et al. Merkel cell carcinoma and multiple primary cancers. Cancer Epidemiol Biomarkers Prev, 2006, 15(8): 1545-1549.
49.	Guan X, Jin Y, Chen Y, et al. The incidence characteristics of second primary malignancy after diagnosis of primary colon and rectal cancer: A population based study. PLoS One, 2015, 10(11): e0143067.
50.	Muller J, Grosclaude P, Lapôtre-Ledoux B, et al. Trends in the risk of second primary cancer among bladder cancer survivors: A population-based cohort of 10 047 patients. BJU Int, 2016, 118(1): 53-59.
51.	梁智恒, 李柱明, 刘宁. 1970-2019年广东省中山市多原发恶性肿瘤发病分析. 中国肿瘤, 2023, 32(4): 265-271.
52.	Weeden CE, Hill W, Lim EL, et al. Impact of risk factors on early cancer evolution. Cell, 2023, 186(8): 1541-1563.
53.	Esposito K, Chiodini P, Colao A, et al. Metabolic syndrome and risk of cancer: A systematic review and meta-analysis. Diabetes Care, 2012, 35(11): 2402-2411.
54.	Malhotra J, Malvezzi M, Negri E, et al. Risk factors for lung cancer worldwide. Eur Respir J, 2016, 48(3): 889-902.
55.	Hecht SS. Tobacco carcinogens, their biomarkers and tobacco-induced cancer. Nat Rev Cancer, 2003, 3(10): 733-744.
56.	Hecht SS. Tobacco smoke carcinogens and lung cancer. J Natl Cancer Inst, 1999, 91(14): 1194-1210.
57.	Hoffmann D, Hoffmann I, El-Bayoumy K. The less harmful cigarette: A controversial issue. A tribute to Ernst L. Wynder. Chem Res Toxicol, 2001, 14(7): 767-790.
58.	Pfeifer GP, Denissenko MF, Olivier M, et al. Tobacco smoke carcinogens, DNA dam age and p53 mutations in smoking-associated cancers. Oncogene, 2002, 21(48): 7435-7451.
59.	Hayes RB, Yin SN, Dosemeci M, et al. Mortality among benzene-exposed workers in China. Environ Health Perspect, 1996, 104(SUPPL.6): 1349-1352.
60.	Flaks A, Hamilton JM, Clayson DB. Effect of ammonium chloride on incidence of bladder tumors induced by 4 ethylsulfonylnaphthalene 1 sulfonamide. J Natl Cancer Inst, 1973, 51(6): 2007-2008.
61.	Human papillomaviruses. IARC monographs on the evaluation of carcinogenic risks to humans. World Health Organization, International Agency for Research on Cancer, 1995, 64: 1-378.
62.	Szukalska M, Szyfter K, Florek E, et al. Electronic cigarettes and head and neck cancer risk-current state of art. Cancers (Basel), 2020, 12(11): 3274 .
63.	Luo K, Luo X, Cao W, et al. Cigarette smoking enhances the metabolic activation of the polycyclic aromatic hydrocarbon phenanthrene in humans. Carcinogenesis, 2021, 42(4): 570-577.
64.	Phillips DH. Smoking-related DNA and protein adducts in human tissues. Carcinogenesis, 2002, 23(12): 1979-2004.
65.	Preussmann R, Stewart BW. N-Nitroso carcinogens. Chemical Carcinogens, 1984, 2(2): 643-828.
66.	Hoffmann D, Djordjevic MV, Fan J, et al. Five leading U. S. Commercial brands of moist snuff in 1994: Assessment of carcinogenic N-nitrosamines. J Natl Cancer Inst, 1995, 87(24): 1862-1869.
67.	Hoffmann D, Adams JD, Lisk D, et al. Toxic and carcinogenic agents in dry and moist snuff. J Natl Cancer Inst, 1987, 79(6): 1281-1286.
68.	Hecht SS, Hoffmann D. Tobacco-specific nitrosamines, an important group of carcinogens in tobacco and tobacco smoke. Carcinogenesis, 1988, 9(6): 875-884.
69.	Vainio H, Weiderpass E. Smokeless tobacco: Harm reduction or nicotine overload? Eur J Cancer Prev, 2003, 12(2): 89-92.
70.	Hecht SS. Biochemistry, biology, and carcinogenicity of tobacco-specific N- nitrosamines. Chem Res Toxicol, 1998, 11(6): 559-603.
71.	Hoffmann D, Hecht SS. Advances in tobacco carcinogenesis. In: Cooper CS and Grover PL (eds) Chemical Carcinogenesis and MutagenesisⅠ. Handbook of Experimental Pharmacology. Berlin, Heidelberg: Springer, 1990. 63-102.
72.	Hecht SS, Rivenson A, Braley J, et al. Induction of oral cavity tumors in F344 rats by tobacco-specific nitrosamines and snuff. Cancer Res, 1986, 46(8): 4162-4166.
73.	Hecht SS, Hoffmann D. The relevance of tobacco-specific nitrosamines to human cancer. Cancer Surveys, 1989, 8(2): 273-294.
74.	Hecht SS, Mirvish SS, Gold B, et al. Conference on advances in the biology and chemistry of N-nitroso and related compounds. Cancer Res, 1989, 49(5): 1327-1329.
75.	Hecht SS, Carmella S, Hoffmann D, et al. A study of tobacco carcinogenesis. XX. Role of catechol as a major cocarcinogen in the weakly acidic fraction of smoke condensate. J Natl Cancer Inst, 1981, 66(1): 163-169.
76.	Turner MC, Cogliano V, Guyton K, et al. Research recommendations for selected IARC-classified agents: Impact and lessons learned. Environ Health Perspect, 2023, 131(10): 105001.
77.	Rivenson A, Hoffmann D, Prokopczyk B, et al. Induction of lung and exocrine pancreas tumors in F344 Rats by tobacco-specific and areca-derived N-Nitrosamines. Cancer Res, 1988, 48(23): 6912-6917.
78.	Prokopczyk B, Hoffmann D, Bologna M, et al. Identification of tobacco-derived compounds in human pancreatic juice. Chem Res Toxicol, 2002, 15(5): 677-685.
79.	Prokopczyk B, Trushin N, Leszczynska J, et al. Human cervical tissue metabolizes the tobacco-specific nitrosamine, 4-(methylnitrosamino)-1-(3-pyridyl)-1-butanone, via α-hydroxylation and carbonyl reduction pathways. Carcinogenesis, 2001, 22(1): 107-114.
80.	Melikian AA, Sun P, Prokopczyk B, et al. Identification of benzo[a]pyrene metabolites in cervical mucus and DNA adducts in cervical tissues in humans by gas chromatography-mass spectrometry. Cancer Letters, 1999, 146(2): 127-134.
81.	Skipper PL, Tannenbaum SR. Protein adducts in the molecular dosimetry of chemical carcinogens. Carcinogenesis, 1990, 11(4): 507-518.
82.	Skipper PL, Peng X, Soohoo CK, et al. Protein adducts as biomarkers of human carcinogen exposure. Drug Metabolism Reviews, 1994, 26(1-2): 111-124.
83.	Landi MT, Zocchetti C, Bernucci I, et al. Cytochrome P4501A2: Enzyme induction and genetic control in determining 4-aminobiphenyl-hemoglobin adduct levels. Cancer Epidemiol Biomarkers Prev, 1996, 5(9): 693-698.
84.	Probst-Hensch NM, Bell DA, Watson MA, et al. N-acetyltransferase 2 phenotype but not NAT1*10 genotype affects aminobiphenyl-hemoglobin adduct levels. Cancer Epidemiol Biomarkers Prev, 2000, 9(6): 619-623.
85.	Castelao JE, Yuan JM, Skipper PL, et al. Gender- and smoking- related bladder cancer risk. J Natl Cancer Inst, 2001, 93(7): 538-545.
86.	Baan RA, Straif K. The monographs programme of the International Agency for Research on Cancer: A brief history of its preamble. Altex, 2022, 39(3): 443-450.
87.	肖琳, 南奕, 邸新博, 等. 2018年中国15岁及以上人群吸烟现况及变化趋势研究. 中华流行病学杂志, 2022, 43(6): 811-817.
88.	Reitsma MB, Fullman N, Ng M, et al. Smoking prevalence and attributable disease burden in 195 countries and territories, 1990–2015: A systematic analysis from the Global Burden of Disease Study 2015. The Lancet, 2017, 389(10082): 1885-1906.
89.	de Martel C, Georges D, Bray F, et al. Global burden of cancer attributable to infections in 2018: A worldwide incidence analysis. Lancet Glob Health, 2020, 8(2): e180-e190.
90.	Zhou XZ, Lyu NH, Zhu HY, et al. Large-scale, national, family-based epidemiological study on Helicobacter pylori infection in China: The time to change practice for related disease prevention. Gut, 2023, 72(5): 855-869.
91.	Yang X, Li Y, Tang Y, et al. Cervical HPV infection in Guangzhou, China: An epidemiological study of 198, 111 women from 2015 to 2021. Emerg Microbes Infect, 2023, 12(1): e2176009.
92.	邹小农, 贾漫漫, 王鑫, 等. 《2020全球癌症报告》要点解读. 中国胸心血管外科临床杂志, 2021, 28(1): 11-18.
93.	Boffetta P, Hashibe M. Alcohol and cancer. Lancet Oncol. 2006, 7(2): 149-156.
94.	Wang YH, Li JQ, Shi JF, et al. Depression and anxiety in relation to cancer incidence and mortality: A systematic review and meta-analysis of cohort studies. Mol Psychiatry, 2020, 25(7): 1487-1499.
95.	Ryan DH. Guidelines for obesity management. Endocrinol Metab Clin North Am, 2016, 45(3): 501-510.
96.	Renehan AG, Tyson M, Egger M, et al. Body-mass index and incidence of cancer: A systematic review and meta-analysis of prospective observational studies. Lancet, 2008, 371(9612): 569-578.
97.	Vithayathil M, Carter P, Kar S, et al. Body size and composition and risk of site-specific cancers in the UK Biobank and large international consortia: A mendelian randomisation study. PLoS Med, 2021, 18(7): e1003706.
98.	Iyengar NM, Gucalp A, Dannenberg AJ, et al. Obesity and cancer mechanisms: Tumor microenvironment and inflammation. J Clin Oncol, 2016, 34(35): 4270-4276.
99.	Pischon T, Nöthlings U, Boeing H. Obesity and cancer. Proc Nutr Soc, 2008, 67(2): 128-145.

1. Zheng RS, Zhang SW, Sun KX, et al. Cancer statistics in China, 2016. Zhonghua Zhong Liu Za Zhi, 2023, 45(3): 212-220.
2. Wei W, Zeng H, Zheng R, et al. Cancer registration in China and its role in cancer prevention and control. Lancet Oncol, 2020, 21(7): e342-e349.
3. Fan L, Strasser-Weippl K, Li JJ, et al. Breast cancer in China. Lancet Oncol, 2014, 15(7): e279-e289.
4. Xi L, Zhu J, Zhang H, et al. Epidemiological trends in gastrointestinal cancers in China: An ecological study. Dig Dis Sci, 2019, 64(2): 532-543.
5. Deo SVS, Sharma J, Kumar S. GLOBOCAN 2020 report on global cancer burden: Challenges and opportunities for surgical oncologists. Ann Surg Oncol, 2022, 29(11): 6497-6500.
6. Lu Y, Song S, Wang R, et al. Impacts of soil and water pollution on food safety and health risks in China. Environ Int, 2015, 77: 5-15.
7. Liu J, Zhang S, Wang Q, et al. Seroepidemiology of hepatitis B virus infection in 2 million men aged 21-49 years in rural China: A population-based, cross-sectional study. Lancet Infect Dis, 2016, 16(1): 80-86.
8. Jiafang Z, Jiachun W, Yunxia L, et al. Alcohol abuse in a metropolitan city in China: A study of the prevalence and risk factors. Addiction, 2004, 99(9): 1103-1110.
9. Ma Z, Lv J, Zhu M, et al. Lung cancer risk score for ever and never smokers in China. Cancer Commun (Lond), 2023, 43(8): 877-895.
10. Mema SC, Baytalan G. Radon and lung cancer risk. CMAJ, 2023, 195(24): E850.
11. Arnold M, Abnet CC, Neale RE, et al. Global burden of 5 major types of gastrointestinal cancer. Gastroenterology, 2020, 159(1): 335-349.
12. Feng X, Wang F, Yang W, et al. Association between genetic risk, adherence to healthy lifestyle behavior, and thyroid cancer risk. JAMA Netw Open, 2022, 5(12): e2246311.
13. Johnstone SE, Gladyshev VN, Aryee MJ, et al. Epigenetic clocks, aging, and cancer. Science, 2022, 378(6626): 1276-1277.
14. Yang J, Siri JG, Remais JV, et al. The Tsinghua-Lancet commission on healthy cities in China: Unlocking the power of cities for a healthy China. Lancet, 2018, 391(10135): 2140-2184.
15. Lester SP, Kaur AS, Vegunta S. Association between lifestyle changes, mammographic breast density, and breast cancer. Oncologist, 2022, 27(7): 548-554.
16. Ullmann TM, Papaleontiou M, Sosa JA. Current controversies in low-risk differentiated thyroid cancer: Reducing overtreatment in an era of overdiagnosis. J Clin Endocrinol Metab, 2023, 108(2): 271-280.
17. Miller KD, Fidler-Benaoudia M, Keegan TH, et al. Cancer statistics for adolescents and young adults, 2020. CA Cancer J Clin, 2020, 70(6): 443-459.
18. 黄渺新, 钟福兴, 郭少华, 等. 对恶性肿瘤年轻化趋势的分析研究. 中国医师进修杂志, 2006, 29(9): 53-54.
19. Li X, Zheng R, Li X, et al. Trends of incidence rate and age at diagnosis for cervical cancer in China, from 2000 to 2014. Chin J Cancer Res, 2017, 29(6): 477-486.
20. Sung H, Ferlay J, Siegel RL, et al. Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA, 2021, 71(3): 209-249.
21. Kjaer TK, Andersen EAW, Ursin G, et al. Cumulative incidence of second primary cancers in a large nationwide cohort of Danish cancer survivors: A population-based retrospective cohort study. Lancet Oncol, 2023, S1470-2045, Epub ahead of print.
22. 赵洁敏, 吴昌平. 多原发癌症的研究进展. 癌症进展, 2016, 14(12): 1195-1198.
23. Ye Y, Neil AL, Wills KE, et al. Temporal trends in the risk of developing multiple primary cancers: A systematic review. BMC Cancer, 2016, 16(1): 849.
24. Curtis RE, Freedman DM, Ron E, et al. New malignancies among cancer survivors: SEER Cancer Registries, 1973-2000. J Epidemiol Comm Health, 2008, 62(4): 375-376.
25. Buzzoni C, Crocetti E, Bella F, et al. Italian cancer figures, report 2013: Multiple tumours. Epidemiol Prev, 2013, 37(4-5): 1-156.
26. Jégu J, Colonna M, Daubisse-Marliac L, et al. The effect of patient characteristics on second primary cancer risk in France. BMC Cancer, 2014, 14: 94.
27. Youlden DR, Baade PD. The relative risk of second primary cancers in Queensland, Australia: A retrospective cohort study. BMC Cancer, 2011, 11: 83.
28. Sankila R, Pukkala E, Teppo L. Risk of subsequent malignant neoplasms among 470, 000 cancer patients in Finland, 1953-1991. Int J Cancer, 1995, 60(4): 464-470.
29. Tsukuma H, Fujimoto I, Hanai A, et al. Incidence of second primary cancers in Osaka residents, Japan, with special reference to cumulative and relative risks. Jpn J Cancer Res, 1994, 85(4): 339-345.
30. Rebora P, Czene K, Antolini L, et al. Are chronic myeloid leukemia patients more at risk for second malignancies? A population-based study. Am J Epidemiol, 2010, 172(9): 1028-1033.
31. Schöllkopf C, Rosendahl D, Rostgaard K, et al. Risk of second cancer after chronic lymphocytic leukemia. Int J Cancer, 2007, 121(1): 151-156.
32. Hisada M, Chen BE, Jaffe ES, et al. Second cancer incidence and cause-specific mortality among 3104 patients with hairy cell leukemia: A population-based study. J Natl Cancer Inst, 2007, 99(3): 215-222.
33. Federico M, Zinzani PL, Frassoldati A, et al. Risk of second cancer in patients with hairy cell leukemia: Long-term follow-up. J Clin Oncol, 2002, 20(3): 638-646.
34. Coleman MP, Bell CM, Fraser P. Second primary malignancy after Hodgkin’s disease, ovarian cancer and cancer of the testis: A population-based cohort study. Br J Cancer, 1987, 56(3): 349-355.
35. Rossi C, Jégu J, Mounier M, et al. Risk assessment of second primary cancer according to histological subtype of non-Hodgkin lymphoma. Leuk Lymphoma, 2015, 56(10): 2876-2882.
36. Razavi P, Rand KA, Cozen W, et al. Patterns of second primary malignancy risk in multiple myeloma patients before and after the introduction of novel therapeutics. Blood Cancer J, 2013, 3(6): e121.
37. Mellemkjaer L, Friis S, Olsen JH, et al. Risk of second cancer among women with breast cancer. Int J Cancer, 2006, 118(9): 2285-2292.
38. Brown LM, Chen BE, Pfeiffer RM, et al. Risk of second non-hematological malignancies among 376, 825 breast cancer survivors. Breast Cancer Res Treat, 2007, 106(3): 439-451.
39. Molina-Montes E, Pollán M, Payer T, et al. Risk of second primary cancer among women with breast cancer: A population-based study in Granada (Spain). Gynecol Oncol, 2013, 130(2): 340-345.
40. Cho YY, Lim J, Oh CM, et al. Elevated risks of subsequent primary malignancies in patients with thyroid cancer: A nationwide, population-based study in Korea. Cancer, 2015, 121(2): 259-268.
41. Kim C, Bi X, Pan D, et al. The risk of second cancers after diagnosis of primary thyroid cancer is elevated in thyroid microcarcinomas. Thyroid, 2013, 23(5): 575-582.
42. Joung JY, Lim J, Oh CM, et al. Risk of second primary cancer among prostate cancer patients in Korea: A population-based cohort study. PLoS One, 2015, 10(10): e0140693.
43. Levi F, Randimbison L, Te VC, et al. Second primary tumors after prostate carcinoma. Cancer, 1999, 86(8): 1567-1570.
44. Bao X, Cao L, Piao H, et al. Treatment-related secondary cancer in malignant meningiomas: A population-based study. J Cancer Res Clin Oncol, 2014, 140(4): 583-588.
45. Jégu J, Binder-Foucard F, Borel C, et al. Trends over three decades of the risk of second primary cancer among patients with head and neck cancer. Oral Oncol, 2013, 49(1): 9-14.
46. Zhu G, Chen Y, Zhu Z, et al. Risk of second primary cancer after treatment for esophageal cancer: A pooled analysis of nine cancer registries. Dis Esophagus, 2012, 25(6): 505-511.
47. Scélo G, Boffetta P, Autier P, et al. Associations between ocular melanoma and other primary cancers: An international population-based study. Inter J Cancer, 2007, 120(1): 152-159.
48. Howard RA, Dores GM, Curtis RE, et al. Merkel cell carcinoma and multiple primary cancers. Cancer Epidemiol Biomarkers Prev, 2006, 15(8): 1545-1549.
49. Guan X, Jin Y, Chen Y, et al. The incidence characteristics of second primary malignancy after diagnosis of primary colon and rectal cancer: A population based study. PLoS One, 2015, 10(11): e0143067.
50. Muller J, Grosclaude P, Lapôtre-Ledoux B, et al. Trends in the risk of second primary cancer among bladder cancer survivors: A population-based cohort of 10 047 patients. BJU Int, 2016, 118(1): 53-59.
51. 梁智恒, 李柱明, 刘宁. 1970-2019年广东省中山市多原发恶性肿瘤发病分析. 中国肿瘤, 2023, 32(4): 265-271.
52. Weeden CE, Hill W, Lim EL, et al. Impact of risk factors on early cancer evolution. Cell, 2023, 186(8): 1541-1563.
53. Esposito K, Chiodini P, Colao A, et al. Metabolic syndrome and risk of cancer: A systematic review and meta-analysis. Diabetes Care, 2012, 35(11): 2402-2411.
54. Malhotra J, Malvezzi M, Negri E, et al. Risk factors for lung cancer worldwide. Eur Respir J, 2016, 48(3): 889-902.
55. Hecht SS. Tobacco carcinogens, their biomarkers and tobacco-induced cancer. Nat Rev Cancer, 2003, 3(10): 733-744.
56. Hecht SS. Tobacco smoke carcinogens and lung cancer. J Natl Cancer Inst, 1999, 91(14): 1194-1210.
57. Hoffmann D, Hoffmann I, El-Bayoumy K. The less harmful cigarette: A controversial issue. A tribute to Ernst L. Wynder. Chem Res Toxicol, 2001, 14(7): 767-790.
58. Pfeifer GP, Denissenko MF, Olivier M, et al. Tobacco smoke carcinogens, DNA dam age and p53 mutations in smoking-associated cancers. Oncogene, 2002, 21(48): 7435-7451.
59. Hayes RB, Yin SN, Dosemeci M, et al. Mortality among benzene-exposed workers in China. Environ Health Perspect, 1996, 104(SUPPL.6): 1349-1352.
60. Flaks A, Hamilton JM, Clayson DB. Effect of ammonium chloride on incidence of bladder tumors induced by 4 ethylsulfonylnaphthalene 1 sulfonamide. J Natl Cancer Inst, 1973, 51(6): 2007-2008.
61. Human papillomaviruses. IARC monographs on the evaluation of carcinogenic risks to humans. World Health Organization, International Agency for Research on Cancer, 1995, 64: 1-378.
62. Szukalska M, Szyfter K, Florek E, et al. Electronic cigarettes and head and neck cancer risk-current state of art. Cancers (Basel), 2020, 12(11): 3274 .
63. Luo K, Luo X, Cao W, et al. Cigarette smoking enhances the metabolic activation of the polycyclic aromatic hydrocarbon phenanthrene in humans. Carcinogenesis, 2021, 42(4): 570-577.
64. Phillips DH. Smoking-related DNA and protein adducts in human tissues. Carcinogenesis, 2002, 23(12): 1979-2004.
65. Preussmann R, Stewart BW. N-Nitroso carcinogens. Chemical Carcinogens, 1984, 2(2): 643-828.
66. Hoffmann D, Djordjevic MV, Fan J, et al. Five leading U. S. Commercial brands of moist snuff in 1994: Assessment of carcinogenic N-nitrosamines. J Natl Cancer Inst, 1995, 87(24): 1862-1869.
67. Hoffmann D, Adams JD, Lisk D, et al. Toxic and carcinogenic agents in dry and moist snuff. J Natl Cancer Inst, 1987, 79(6): 1281-1286.
68. Hecht SS, Hoffmann D. Tobacco-specific nitrosamines, an important group of carcinogens in tobacco and tobacco smoke. Carcinogenesis, 1988, 9(6): 875-884.
69. Vainio H, Weiderpass E. Smokeless tobacco: Harm reduction or nicotine overload? Eur J Cancer Prev, 2003, 12(2): 89-92.
70. Hecht SS. Biochemistry, biology, and carcinogenicity of tobacco-specific N- nitrosamines. Chem Res Toxicol, 1998, 11(6): 559-603.
71. Hoffmann D, Hecht SS. Advances in tobacco carcinogenesis. In: Cooper CS and Grover PL (eds) Chemical Carcinogenesis and MutagenesisⅠ. Handbook of Experimental Pharmacology. Berlin, Heidelberg: Springer, 1990. 63-102.
72. Hecht SS, Rivenson A, Braley J, et al. Induction of oral cavity tumors in F344 rats by tobacco-specific nitrosamines and snuff. Cancer Res, 1986, 46(8): 4162-4166.
73. Hecht SS, Hoffmann D. The relevance of tobacco-specific nitrosamines to human cancer. Cancer Surveys, 1989, 8(2): 273-294.
74. Hecht SS, Mirvish SS, Gold B, et al. Conference on advances in the biology and chemistry of N-nitroso and related compounds. Cancer Res, 1989, 49(5): 1327-1329.
75. Hecht SS, Carmella S, Hoffmann D, et al. A study of tobacco carcinogenesis. XX. Role of catechol as a major cocarcinogen in the weakly acidic fraction of smoke condensate. J Natl Cancer Inst, 1981, 66(1): 163-169.
76. Turner MC, Cogliano V, Guyton K, et al. Research recommendations for selected IARC-classified agents: Impact and lessons learned. Environ Health Perspect, 2023, 131(10): 105001.
77. Rivenson A, Hoffmann D, Prokopczyk B, et al. Induction of lung and exocrine pancreas tumors in F344 Rats by tobacco-specific and areca-derived N-Nitrosamines. Cancer Res, 1988, 48(23): 6912-6917.
78. Prokopczyk B, Hoffmann D, Bologna M, et al. Identification of tobacco-derived compounds in human pancreatic juice. Chem Res Toxicol, 2002, 15(5): 677-685.
79. Prokopczyk B, Trushin N, Leszczynska J, et al. Human cervical tissue metabolizes the tobacco-specific nitrosamine, 4-(methylnitrosamino)-1-(3-pyridyl)-1-butanone, via α-hydroxylation and carbonyl reduction pathways. Carcinogenesis, 2001, 22(1): 107-114.
80. Melikian AA, Sun P, Prokopczyk B, et al. Identification of benzo[a]pyrene metabolites in cervical mucus and DNA adducts in cervical tissues in humans by gas chromatography-mass spectrometry. Cancer Letters, 1999, 146(2): 127-134.
81. Skipper PL, Tannenbaum SR. Protein adducts in the molecular dosimetry of chemical carcinogens. Carcinogenesis, 1990, 11(4): 507-518.
82. Skipper PL, Peng X, Soohoo CK, et al. Protein adducts as biomarkers of human carcinogen exposure. Drug Metabolism Reviews, 1994, 26(1-2): 111-124.
83. Landi MT, Zocchetti C, Bernucci I, et al. Cytochrome P4501A2: Enzyme induction and genetic control in determining 4-aminobiphenyl-hemoglobin adduct levels. Cancer Epidemiol Biomarkers Prev, 1996, 5(9): 693-698.
84. Probst-Hensch NM, Bell DA, Watson MA, et al. N-acetyltransferase 2 phenotype but not NAT1*10 genotype affects aminobiphenyl-hemoglobin adduct levels. Cancer Epidemiol Biomarkers Prev, 2000, 9(6): 619-623.
85. Castelao JE, Yuan JM, Skipper PL, et al. Gender- and smoking- related bladder cancer risk. J Natl Cancer Inst, 2001, 93(7): 538-545.
86. Baan RA, Straif K. The monographs programme of the International Agency for Research on Cancer: A brief history of its preamble. Altex, 2022, 39(3): 443-450.
87. 肖琳, 南奕, 邸新博, 等. 2018年中国15岁及以上人群吸烟现况及变化趋势研究. 中华流行病学杂志, 2022, 43(6): 811-817.
88. Reitsma MB, Fullman N, Ng M, et al. Smoking prevalence and attributable disease burden in 195 countries and territories, 1990–2015: A systematic analysis from the Global Burden of Disease Study 2015. The Lancet, 2017, 389(10082): 1885-1906.
89. de Martel C, Georges D, Bray F, et al. Global burden of cancer attributable to infections in 2018: A worldwide incidence analysis. Lancet Glob Health, 2020, 8(2): e180-e190.
90. Zhou XZ, Lyu NH, Zhu HY, et al. Large-scale, national, family-based epidemiological study on Helicobacter pylori infection in China: The time to change practice for related disease prevention. Gut, 2023, 72(5): 855-869.
91. Yang X, Li Y, Tang Y, et al. Cervical HPV infection in Guangzhou, China: An epidemiological study of 198, 111 women from 2015 to 2021. Emerg Microbes Infect, 2023, 12(1): e2176009.
92. 邹小农, 贾漫漫, 王鑫, 等. 《2020全球癌症报告》要点解读. 中国胸心血管外科临床杂志, 2021, 28(1): 11-18.
93. Boffetta P, Hashibe M. Alcohol and cancer. Lancet Oncol. 2006, 7(2): 149-156.
94. Wang YH, Li JQ, Shi JF, et al. Depression and anxiety in relation to cancer incidence and mortality: A systematic review and meta-analysis of cohort studies. Mol Psychiatry, 2020, 25(7): 1487-1499.
95. Ryan DH. Guidelines for obesity management. Endocrinol Metab Clin North Am, 2016, 45(3): 501-510.
96. Renehan AG, Tyson M, Egger M, et al. Body-mass index and incidence of cancer: A systematic review and meta-analysis of prospective observational studies. Lancet, 2008, 371(9612): 569-578.
97. Vithayathil M, Carter P, Kar S, et al. Body size and composition and risk of site-specific cancers in the UK Biobank and large international consortia: A mendelian randomisation study. PLoS Med, 2021, 18(7): e1003706.
98. Iyengar NM, Gucalp A, Dannenberg AJ, et al. Obesity and cancer mechanisms: Tumor microenvironment and inflammation. J Clin Oncol, 2016, 34(35): 4270-4276.
99. Pischon T, Nöthlings U, Boeing H. Obesity and cancer. Proc Nutr Soc, 2008, 67(2): 128-145.

Chinese Journal of Clinical Thoracic and Cardiovascular Surgery

Interpretation of the key points of Cancer Incidence and Mortality in China, 2016

Abstract Full text Figures/Tables Video References Cited by

Previous Article

Next Article

Format

Content